| Image Class: | skin-invert-image |
| Class: | Monoamine releasing agent |
| Cas Number: | 201474-93-3 |
| Pubchem: | 85764579 |
| Chemspiderid: | 129433781 |
| Unii: | TBJ4S8YF37 |
| Synonyms: | 3,4-Methylenedioxy-N-propylcathinone; MD-PrC; PrONE; bk-3,4-MDPA |
| Iupac Name: | 1-(1,3-benzodioxol-5-yl)-2-(propylamino)propan-1-one |
| C: | 13 |
| H: | 17 |
| N: | 1 |
| O: | 3 |
| Smiles: | CCCNC(C)C(=O)C1=CC2=C(C=C1)OCO2 |
| Stdinchi: | 1S/C13H17NO3/c1-3-6-14-9(2)13(15)10-4-5-11-12(7-10)17-8-16-11/h4-5,7,9,14H,3,6,8H2,1-2H3 |
| Stdinchikey: | YFVKHKCZBSGZPE-UHFFFAOYSA-N |
Propylone, also known as 3,4-methylenedioxy-N-propylcathinone is a mixed monoamine releasing agent and reupake inhibitor of the cathinone family related to methylone and ethylone.[1]
It acts specifically as a weak partial serotonin–dopamine releasing agent (SDRA) and serotonin–norepinephrine–dopamine reuptake inhibitor (SNDRI), with values for induction of monoamine release of 3,128nM (30%) for serotonin and 976nM (20%) for dopamine, and value for monoamine reuptake inhibition of 2,462nM for serotonin, 28,540nM for norepinephrine, and 1,863nM for dopamine.
The drug was first described in the literature in a 1996 patent by Alexander Shulgin and Peyton Jacob III.[2] It was subsequently characterized more thoroughly by 2015 and was encountered as a novel designer drug in Europe by 2016.[3] [4] [5]
